Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.
Visit our Writing Guide or this topic page for additional help.
Timeline
July 2012
PsiOxus Therapeutics raises a $22,000,000 series B round from Imperial Innovations, Invesco Perpetual and SR One.
Funding Rounds
Patents
Further Resources
Title
Author
Link
Type
Date
News
Title
Author
Date
Publisher
Description
Nick Paul
April 14, 2021
FierceBiotech
Bluebird bio has shown cancer gene therapy vectors boost the efficacy of its CAR-T therapy in mice. The study assessed the effect of giving bluebird's anti-EGFR CAR-T cells in combination with vectors in development at PsiOxus Therapeutics.
Amirah Al Idrus
April 7, 2021
FierceBiotech
Bristol Myers Squibb and PsiOxus are expanding their partnership--again. The duo first teamed up in June 2016 to study the latter's cancer-killing virus, inking a deal later that year to combine the virus with BMS' checkpoint inhibitor, Opdivo. Now, they're adding a second asset from PsiOxus to the mix.
References
Organization
CompanyCompany attributes
Vaccine
Biomedical engineering
Biopharmaceutical
Oncolytic virus
Technology
CancerLocation
Oxfordshire
Oxford
United KingdomB2X
B2BFounder
Pitchbook URL
Parent Organization
Imperial College London
Imperial Innovations
SR One
Bristol-Myers Squibb
IP GroupFounded Date
2006
Email Address
enquiries@psioxus.com
Total Funding Amount (USD)
22,000,000
Latest Funding Round Date
July 2012
Business Model
Commerce
Latest Funding Type
Series B round